• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    TransMedics Announces OCS Technology used in First US Patients

    Jocelyn Aspa
    Dec. 04, 2019 09:14AM PST
    Medical Device Investing

    The company has completed the first successful human heart transplants at Duke University Hospital and Massachusetts General Hospital.

    TransMedics Group (NASDAQ:TMDX) has announced it has finished the first human heart transplants from donation after circulatory death (DCD) donors in the US at Duke University Hospital and Massachusetts General Hospital.

    As quoted in the press release:

    These transplants were made possible by the company’s OCS Heart System, which is being evaluated for use in DCD heart transplants across several U.S. heart transplant centers in an ongoing pivotal clinical trial.

    A DCD donor is one in which the donation process could start only after the heart has stopped beating.  Currently, DCD donors are not considered for heart transplantation due to the potential injury that takes place once the heart stops beating and lack of any viability assessment capabilities using cold static storage.  With the TransMedics OCS™ Heart System, the donor heart is retrieved, resuscitated to normal beating state and then clinically assessed before transplantation.  The OCS™ Heart System is the only medical device that has enabled DCD heart transplantation to become a clinical reality and to date has also been utilized in the UK and Australia.

    “This a critical milestone for U.S. heart transplantation that could enable a significant increase in heart transplant procedures to help many end-stage heart failure patients,” said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. “We are looking forward to the continued progress of this important clinical trial and the continued adoption of OCS as the next standard of care for heart, lung and liver transplants,” said Dr. Hassanein.

    Click here to read the full press release.

    medical device investingtransmedics groupnasdaq:tmdxunited states
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Cardiex Limited (ASX:CDX)

    Cardiex Limited

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—